Citadel Advisors’s Artiva Biotherapeutics ARTV Stock Holding History
Bought
Maintained
Sold
Other funds holding ARTV
Citadel Advisors's ARTV Position: Q3 2026 in Review
Citadel Advisors reduced its Artiva Biotherapeutics (ARTV) stake by 97% in Q3 2026, selling an estimated $5.98M and leaving 16,397 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #12796.
Citadel Advisors first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.91M in Q2 2026. 98 funds tracked by Wall St. Rank hold ARTV as of Q3 2026.
- Citadel Advisors held 16,397 shares of Artiva Biotherapeutics worth $117K as of Q3 2026.
- Citadel Advisors sold 592,979 Artiva Biotherapeutics shares in Q3 2026, an estimated $5.98M.
- Artiva Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #12796 holding.
- Citadel Advisors first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
- Citadel Advisors's Artiva Biotherapeutics position peaked at $5.91M in Q2 2026.
- 98 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.